Neuvasq Biotechnologies participated in the 2025 J.P. Morgan Healthcare Conference, a key event in the global biotech and pharmaceutical calendar.
Dr. Ralph Laufer (Chief Scientific Officer) and Emmanuel Lacroix (Chief Executive Officer) represented the company in San Francisco, engaging with potential partners and investors.
This was the opportunity to share preclinical evidences demonstrating the successful engineering of innovative, highly potent Wnt surrogate antibodies that restore the integrity of the blood-retinal barrier in preclinical models of vascular retinopathy.
Neuvasq’s lead program focuses on the development of engineered Wnt surrogate antibodies targeting Gpr124 and Reck, critical co-receptors in Wnt/β-catenin signaling.
Back to news
Cookie policy